Business
Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference
Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference Mont-Saint-Guibert, Belgium – December 29, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the management team will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, Jan. 15
About this update from Nyxoah Sa
[{"type":"image","alt":"Nyxoah","displaySize":"","headline":null,"caption":"Nyxoah","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":103,"url":"https://media.zenfs.com/en/globenewswire.com/e7e3b117995786ca545ccd418ff4f6d2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tAkvChng_2zCp_EwJSkW7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e7e3b117995786ca545ccd418ff4f6d2","width":300,"height":103}},"lazy":false},{"type":"text","content":"Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference","length":70,"tagName":"p"},{"type":"text","content":"Mont-Saint-Guibert, Belgium – December 29, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the management team will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, Jan. 15, 2026. The Company's presentation will begin at 12:00 pm PT.","length":494,"tagName":"p"},{"type":"text","content":"A live audio webcast of the presentation will be available online on the investor relations page of the Company’s website at investors.nyxoah.com.","length":146,"tagName":"p"},{"type":"text","content":"About NyxoahNyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.","length":547,"tagName":"p"},{"type":"text","content":"Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Colla...